Evidence map›Paper›PMID 41721121›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Dual inhibition of MMP-2 and actin dynamics by a novel bis-chalcone: an anticancer strategy for oral squamous cell carcinoma.

Rodrigo Elísio de Sá, Bruna Oliveira de Almeida, Marcelo da Costa Mota, Matheus Pedrosa de Oliveira, Anali Del Milagro Bernabe Garnique, Keli Lima, Aline Bernardes Valeze, Jefferson Almeida Rocha, Caridad Noda Pérez, João Agostinho Machado Neto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rodrigo Elísio de SáLaboratório de Cultura de Células do Delta (LCCDelta), Universidade Federal Delta do Parnaíba, UFDPar, Parnaíba, PI, Brazil.
Bruna Oliveira de AlmeidaDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, SP, Brazil.
Marcelo da Costa MotaGrupo de Pesquisa Em Química Medicinal E Biotecnologia (QUIMEBIO), Universidade Federal do Maranhão, UFMA, São Bernardo, MA, Brazil.
Matheus Pedrosa de OliveiraLaboratório de Cultura de Células do Delta (LCCDelta), Universidade Federal Delta do Parnaíba, UFDPar, Parnaíba, PI, Brazil.
Anali Del Milagro Bernabe GarniqueDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, SP, Brazil.
Keli LimaDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, SP, Brazil.
Aline Bernardes ValezeDepartamento de Ensino, Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso - IFMT, Cuiabá, MT, Brazil.
Jefferson Almeida RochaGrupo de Pesquisa Em Química Medicinal E Biotecnologia (QUIMEBIO), Universidade Federal do Maranhão, UFMA, São Bernardo, MA, Brazil.
Caridad Noda PérezLaboratório de Sínteses Orgânica e Catálise, Instituto de Química, Universidade Federal de Goiás, UFG, Goiânia, GO, Brazil.
João Agostinho Machado NetoDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, SP, Brazil.
Letícia Veras Costa LotufoDepartamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, SP, Brazil.
José Delano Barreto Marinho FilhoLaboratório de Cultura de Células do Delta (LCCDelta), Universidade Federal Delta do Parnaíba, UFDPar, Parnaíba, PI, Brazil.
Ana Jérsia AraújoLaboratório de Cultura de Células do Delta (LCCDelta), Universidade Federal Delta do Parnaíba, UFDPar, Parnaíba, PI, Brazil. anajersia@ufdpar.edu.br.ORCID 0000-0001-7182-7097

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq grant # 300830/2024-6Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq grant #303048/2022-0National Institute of Science and Technology - INCT BioNat CNPq grant # 465637/2014-0, FAPESP grant # 2014/50926-0, Brazil
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC), accounts for approximately 90% of oral cancer cases, and due to its aggressive nature and limited treatment options remains a significant clinical challenge. In the pursuit of novel therapeutic agents, bis-chalcones (a subclass of chalcones) have emerged as promising candidates with multipronged anticancer potential. In this study, we synthesized and evaluated a novel bis-chalcone (B2OCH

Indexed as

ActinsAntineoplastic AgentsCarcinoma, Squamous CellChalconeChalconesMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMouth NeoplasmsCell AdhesionCell Line, TumorCell MovementCell SurvivalHumansMolecular Docking SimulationActinsAntineoplastic AgentsChalconeChalconesMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMMP2 protein, humanCell invasionCell migrationMetalloproteinasesOral squamous cell carcinomaSymmetrical bis-chalcone

Identifiers

PMID41721121
PMCPMC13269452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.